Abstract
AbstractRenal cell carcinoma represents nearly 90% of all malignant tumors of the kidney. The varied aspects of this tumor's pathophysiology have been a continuing challenge to early diagnosis and successful therapy. For inapparent reasons it has been noted in this and other studies that renal cell carcinoma is twice as common in males as in females. As we have shown, renal cell carcinoma occurs in all age groups but is most common in the sixth and seventh decades. In spite of an occasional case, heredity probably does not apparently play a role in the pathogenesis of this disease. This study has shown that because of the multiple pathways of dissemination, renal cell carcinoma can be unpredictable in the sites of metastasis. The lung, however, is consistently the most common site of metastatic growth. Many experts have attempted to introduce a system of classification related to prognosis. The present experience using the classification of Flocks and Kadesky showed there was a notable drop in survival in stages III and IV as compared to I and II. Also, there was little difference in survival between patients having stage III and stage IV disease. In general, the survival statistics agree with those of others. The classic triad of renal cell carcinoma was associated with 5‐year survival in only four cases, indicating it to be a sign of advanced disease. Radical nephrectomy continues to be the initial treatment in most centers. The most promising of the newer methods is hormonal therapy, which is based on the theory that hormones underlie the mechanism of host resistance to renal cell carcinoma. There have been four satisfactory responses in 26 treated cases of renal tumor with distant metastases. However, it is still too early to make valid statements about this modality.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call